X0306 4 2017-07-31 1 0001618561 Nexvet Biopharma plc NVET 0001275110 PATEL RAJIV A C/O FARALLON CAPITAL MANAGEMENT, L.L.C. ONE MARITIME PLAZA, SUITE 2100 SAN FRANCISCO CA 94111 1 0 0 0 Ordinary Shares 2017-07-31 4 D 0 13580 6.72 D 0 D Restricted Share Units 2017-07-31 4 D 0 1000 6.595 D Ordinary Shares 1000 0 D Each Restricted Share Unit ("RSU") is convertible into one ordinary share of the Issuer upon vesting, subject to payment by the holder to the Issuer of the nominal value per share ($0.125). The 1,000 RSUs held by Patel were scheduled to vest and become convertible in quarterly installments of 500 on September 30, 2017 and December 31, 2017. Such RSUs were canceled in the Acquisition, as described below. Disposed of pursuant to a transaction agreement among the Issuer, Zoetis Inc. ("Zoetis") and Zoetis Belgium S.A., a wholly-owned subsidiary of Zoetis ("Bidco"), pursuant to which Bidco acquired all of the issued and to-be-issued ordinary share capital of the Issuer (the "Acquisition"). These RSUs, which were not yet vested, were cancelled in the Acquisition in exchange for a total cash payment equal to $6,595, representing the difference between the conversion payment of $0.125 per RSU and the $6.72 consideration per ordinary share payable in connection with the Acquisition, multiplied by the 1,000 ordinary shares issuable upon the vesting and conversion of such RSUs. Effective July 31, 2017, Patel resigned as a director of the Issuer upon the consummation of the Acquisition. /s/ Rajiv A. Patel 2017-08-02